Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $8.28M (cash outflow) fell 98.1% year over year, behind the -80.5% change in trailing-twelve-month net income. Sequentially, it fell 79.5% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.

Context

  • Net income amounted to 341.5% of revenue in FY2025, up 140.3 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$131.73M (-75.9%) for the fiscal year ending Dec 2026, a slowdown from the +76.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.28M-79.5% QoQ
Last fiscal yearDec 2025
-$546.38M+76.3% YoY
LTMMar 2026
-$128.58M-80.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.1%+3.9%+102.0 pp
1 year+76.3%-75.9%-152.2 pp
3-year CAGR+20.2%-41.5%-61.8 pp
5-year CAGR-36.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(546.38M) USD
Year-over-year change
-76.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 net income of $128.58M is the 2nd largest of the 3 companies compared; the peer median is $190.09M.
  • Its year-over-year change of -80.5% is the lowest of 3, against a peer median of -21.3%.
  • Net income amounts to 80.3% of revenue for PACB, versus a peer median of 2808.3%.
PACB Competitors Peer median
Net Income for PACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$484M -45.7%—10.8%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$128.58M -80.5%+20.2%80.3%
QSIQuantum-Si incorporatedLTM Mar 2026$103.82M +3.1%-8.5%5605.9%
Peer median (excluding PACB) $190.09M-21.3%-8.5%2808.3%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Depreciation & Amortization11.59M17.32M32.69M53.34M386.41M
Deferred Income Tax(93.65M)0(11.42M)(205K)(546K)
Stock-Based Compensation80.73M78.61M0041.67M
Change in Working Capital21.01M(53.97M)(58.96M)(40.58M)4.44M
Accounts Receivables(7.17M)5.46M(17.83M)9.09M(7.92M)
Inventory(12.43M)(33.91M)(13.84M)(8.32M)(1.42M)
Accounts Payables6.36M1.03M206K1.41M2.48M
Other Working Capital34.24M(26.55M)(27.49M)(42.75M)11.3M
Other Non-Cash Items50.37M9.08M77.88M91.24M3.19M
Operating Cash Flow(111.18M)(263.21M)(266.55M)(206.06M)(111.21M)
Capital Expenditures(5.93M)(16.93M)(8.84M)(6.19M)(2.71M)
Acquisitions (Net)(319.79M)179K(102K)00
Purchases of Investments(988.05M)(442.79M)(756.57M)(498.64M)(216.91M)
Sales of Investments635.24M575.8M770.12M628.83M340.07M
Other Investing Activities0(179K)00(5M)
Investing Cash Flow(678.53M)116.08M4.6M124M115.45M
Debt Repayment895.18M(1.61M)(1.84M)(50.69M)0
Common Stock Issued294.85M11.23M204.52M7.7M3.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.44M)0(86.41M)00
Financing Cash Flow1.17B9.62M116.27M(42.99M)3.43M
Effect of Forex Changes00500K890K0
Net Change in Cash379.87M(137.51M)(145.18M)(124.15M)7.67M
Free Cash Flow(117.11M)(280.14M)(275.39M)(212.25M)(113.92M)

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.